Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer

S.H.I. Ou, S.M. Gadgeel, F. Barlesi, J.C.H. Yang, L. De Petris, D.W. Kim, R. Govindan, A.M. Dingemans, L. Crino, H. Lena, S. Popat, J.S. Ahn, E. Dansin, E. Mitry, B. Muller, W. Bordogna, B. Balas, P.N. Morcos, A.T. Shaw*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Web of Science)
Original languageEnglish
Pages (from-to)22-27
Number of pages6
JournalLung Cancer
Volume139
DOIs
Publication statusPublished - 1 Jan 2020

Keywords

  • alectinib
  • alk
  • crizotinib
  • nsclc
  • overall survival
  • pooled analysis
  • safety
  • ALK
  • NSCLC
  • Pooled analysis
  • Alectinib
  • CRIZOTINIB
  • Safety
  • Overall survival

Cite this